Navigation Links
InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
Date:9/2/2008

a 14-day study of ITMN-191 in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). The study is proceeding as planned. Top-line results from the triple combination study are anticipated to be released in the fourth quarter of 2008.

About Hepatitis C

The hepatitis C virus (HCV) is transmitted primarily through blood or blood products. HCV chronically affects 180 million people worldwide, which makes it over four times more prevalent than HIV. It is a leading cause of cirrhosis, liver cancer and liver failure, despite the fact that many patients can be cured.

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on small molecules for pulmonary disease. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) in Phase 1b, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit http://www.intermune.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and involve risks and uncertainties as of the date of this release, including without limitation the statements related to anticipated product development timelines. All forward-looking statements and other information included
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
6. InterMune to Present at the SIGnificant Options in Healthcare Conference
7. Evotec Expands Collaboration With InterMune
8. Statement by InterMune, Inc. Regarding Justice Department Action Against Former Employee for Past Conduct
9. InterMune to Present at Deutsche Bank Health Care Conference
10. InterMune to Present at Bank of America Health Care Conference
11. InterMune to Present at Citigroup Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... July 10, 2014 Women in ... access to an additional family planning option. Sayana® ... contraception at all levels of the health system ... of a widely used contraceptive—Pfizer’s Depo-Provera® (depot medroxyprogesterone ... Faso is the first of four African countries ...
(Date:7/10/2014)... 2014 Unraveling life’s mysteries can intrigue, ... Archer Family purchased a DNA test to ... up with a lifetime of memories, sharing, and closeness. ... members’ DNA genuinely brought the family closer together. ... into genetic history and prior to taking the ...
(Date:7/10/2014)... July 10, 2014  Franciscan St. Anthony ... capnography for respiratory monitoring outside the operating ... leaders in embracing state-of-the-art patient safety technology. ... are breathing and can alert medical caregivers ... the amount of carbon dioxide the patient ...
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9
... HILLS, Mass., Dec. 5 MacroChem,s,(OTC Bulletin Board: MACM), ... at the upcoming Equities Magazine Winter Discovery,Day Conference XV ... December 7,2007. Mr. DeLuccia is scheduled to present at ... an all day event featuring special,presentations from emerging public ...
... Md., Dec. 5 Micromet, Inc. (Nasdaq:,MITI), a ... antibody-based products for cancer, inflammation and autoimmune,diseases, today ... Officer of Micromet, will be part of a ... Therapies For Cancer" at the 2007,RBC Capital Markets ...
... Dec. 5 Nastech Pharmaceutical,Company Inc. (Nasdaq: NSTK ... study with an undisclosed global leader in the production ... Factor IX protein,which is currently administered by injection to ... "We look forward to working with our new global ...
Cached Biology Technology:MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York 2MacroChem to Present at Equities Magazine Conference December 7, 2007 in New York 3Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007 2Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding 2
(Date:7/11/2014)... animals often develop relationships with other group members to ... wild chacma baboons the strategy for grooming activities shows ... just published in the scientific journal Biology Letters ... baboons is not practiced without ulterior motives. To be ... the individual, while grooming another individual can provide access ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... 1 can inhibit voltage-gated calcium channel, decrease ... However, some scholars demonstrated that cannabinoid receptor ... and increase neurotransmitter release. Dr. Yi Zhang ... Tongji Medical College, Huazhong University of Science ... and calcium imaging in cultured trigeminal ganglion ...
Breaking Biology News(10 mins):Baboons groom early in the day to get benefits later 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... researcher, please contact the Communications and External Relations staff member ... on ORNL and its research and development activities, please refer ... general media-related question or comment, you can send it to ... fuel pellets . . . Oak Ridge ...
... Spain: The numbers of cycles of preimplantation genetic diagnosis ... 2,700 reported in 2004 (the most recent year for ... screen for a growing number of genetically related conditions, ... the targeted condition are available for transfer and the ...
... that gladdens a mother,s heart also lights up the reward ... in a report that appears in the journal Pediatrics ... out the special mother-infant bond and how it sometimes go ... BCM and Texas Children,s Hospital and a research associate in ...
Cached Biology News:Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 2Story tips from the Department of Energy's Oak Ridge National Laboratory, July 2008 3Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 2Should embryos with a hereditary disorder be transferred if no unaffected embryos are available? 3A baby's smile is a natural high 2
Bovine Pulmonary Artery Smooth Muscle Cells (BPASMC) (>500,000 cells)...
... Mouse monoclonal [E12] to MAP1 Light Chain ... the physical interactions between microtubules and components of ... a heavy chain subunit and multiple light chain ... one of the light chain subunits and can ...
Image Acquisition and documentation system for fluorescent and non-fluorescent gels, membranes, blots, film, plates and assays...
PC based system for advanced chemifluorescent, chemiluminescent, fluorescent and colorimetric, microarray and microscope imaging and analysis....
Biology Products: